Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
about
Trabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesEcteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cellsFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Trabectedin and its potential in the treatment of soft tissue sarcoma.Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyLong-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma.Trabectedin: safety and efficacy in the treatment of advanced sarcomaMultidisciplinary management of soft-tissue sarcomas.Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patientsTrabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investmentDevelopments in the management of extremity soft tissue sarcomas.New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdomModulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepatotoxicityA phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Unique features of trabectedin mechanism of action.Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma?Chemotherapy for soft tissue sarcoma.Newer medical therapies for metastatic soft tissue sarcoma.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Bone sarcomas: from biology to targeted therapies.Parallel lives of symbionts and hosts: chemical mutualism in marine animals.New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials†.
P2860
Q26745502-DFF440BD-1D49-4DAE-95A6-500700CF2017Q28307320-366FD3DC-2638-4874-BEAD-71D313AAC423Q30439459-1DDB9747-F36C-49BA-B4F4-8D994DEC8D06Q33379886-B1EB0545-0247-4623-B65B-3D2A713563C7Q33380903-8792AB5E-86A6-4DD9-B558-F63797B46776Q33381641-30EE1A66-8412-4058-950A-F10EFAB48324Q33386535-BB1872F4-DCD0-46DD-AEC0-587B6E8A5C5CQ34578850-93221DD3-7750-4E9F-80D9-5B508B2A129AQ34622323-FAFEF115-78A8-4FE3-92B0-10F03858764FQ34628607-BD3CAFE0-067D-42D5-A9E3-238406AE263CQ34798740-59488C2B-CA78-467C-B858-5DBF096E7797Q35011907-419F0DF0-5786-4820-A78D-20D5E9A52B8FQ35058617-CAAB96D6-12EF-49E1-BA6B-E5659D6B0B81Q35676502-276CCD65-1E5E-43C8-9BF2-35539B92242AQ35898258-C86979F5-E199-465E-8BA9-3968F0E36CE2Q35958048-33EC8BFA-9D39-4350-8FCE-8A42FE1FA8C8Q36353510-6842B7B4-29BD-4CEB-A629-E4A1395DC849Q36444369-9D1C0E35-1883-47B0-8300-53C56EB178A0Q36731032-EF66F089-7A61-457B-950C-627B41084F67Q36948681-6589BFDD-A01B-4A67-9CCA-20C7B2ECF8C6Q37005569-90916691-D038-4859-A5CF-31203B9151CDQ37091695-D4BBFA4A-C3C9-4E05-B4B4-7D8D3C7BA413Q37330372-B5809806-A776-4DF7-B5F3-ED9A452A1208Q38669051-D9BB2E63-D185-420E-9DC3-3AD94034EA8DQ38769613-CB2032BF-533C-416B-873B-E92F5F0B0B3DQ38902113-051E0F68-80CC-4E70-B350-6F46162585D8Q39012067-34AA0553-8260-4872-A5C4-BA27994518CCQ41105379-CC91D71C-40BF-4D15-A07F-7BFDDB4A66C9Q41923624-9052C717-BA84-4417-B7E3-95685A2571C0Q50021280-50F5CC7E-A8E0-4DFC-90B6-3DC0DFE078FEQ55712396-35230053-78BB-4E3F-AD19-6FA28C717BC7
P2860
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@ast
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@en
type
label
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@ast
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@en
prefLabel
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@ast
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@en
P2093
P1476
Ecteinascidin-743: a marine-de ...... liminary evidence of activity.
@en
P2093
E Cvitkovic
F Goldwasser
J L Misset
P304
P356
10.1200/JCO.2001.19.5.1248
P407
P577
2001-03-01T00:00:00Z